Erythromycin Topical Gel USP — Class II drug recall D-0851-2022
Ongoing recall by McKesson Corporation dba McKesson Drug Company, reported 2022-05-11, distributed nationwide. CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma
| Recall number | D-0851-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | McKesson Corporation dba McKesson Drug Company, Memphis, TN, United States |
| Recall initiated | 2022-04-21 |
| Classified | 2022-05-05 |
| Reported by FDA | 2022-05-11 |
| Distributed | Nationwide (US) |
| Quantity | 5,640 tubes |
| Reason classes | cgmp, specification failure |
| NDC | 63739-0053-68 |
| Lot numbers | 15723 |
| Expiration dates | 2022-06-30 |
Product
Erythromycin Topical Gel USP, 2%, Net Wt 60 g tube, Rx only, Manufactured by: Teligent Pharma, Inc. Buena, NJ 08310 Distributed by: McKesson Corporation dba Sky Packaging 4971 Southridge Blvd., Suite 101 Memphis, TN 38141, NDC 63739-053-68
Reason for recall
CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0851-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.